XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income (loss) attributable to Myriad Genetics, Inc. stockholders $ (19.6) $ (185.8)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation and amortization 49.5 53.3
Non-cash interest expense 1.3 0.4
Non-cash lease expense 9.8 9.6
Stock-based compensation expense 27.9 17.8
Deferred income taxes (27.8) (0.6)
Unrecognized tax benefits 1.5 14.9
Change in fair value of contingent consideration 1.7 (4.5)
Loss on inventory 6.5 0.0
Impairment of goodwill and long-lived assets 1.8 98.4
Gain on sale of businesses and assets (162.0) (1.0)
Changes in assets and liabilities:    
Prepaid expenses and other current assets (6.7) 5.4
Trade accounts receivable (11.6) 33.3
Inventory (1.6) 1.7
Prepaid taxes 108.0 (83.2)
Other assets (3.6) (1.2)
Accounts payable (4.8) (2.6)
Accrued liabilities 78.2 3.1
Deferred revenues (20.4) 28.5
Net cash provided by (used in) operating activities 28.1 (12.5)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Capital expenditures (14.6) (6.8)
Proceeds from sale of businesses and assets 379.1 21.3
Purchases of marketable investment securities (101.0) (15.8)
Proceeds from maturities and sales of marketable investment securities 36.8 51.9
Net cash provided by investing activities 300.3 50.6
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from common stock issued under stock-based compensation plans 90.0 2.2
Payment of tax withheld for common stock issued under stock-based compensation plans (8.6) (3.9)
Payment of contingent consideration recognized at acquisition (3.3) (0.1)
Fees associated with refinancing of revolving credit facility (1.2) (1.0)
Repayment of revolving credit facility (226.4) 0.0
Net cash used in financing activities (149.5) (2.8)
Effect of foreign exchange rates on cash and cash equivalents (0.7) 0.3
Change in cash and cash equivalents classified as held for sale 0.0 1.5
Net increase in cash and cash equivalents 178.2 37.1
Cash and cash equivalents at beginning of the period 117.0 81.2
Cash and cash equivalents at end of the period $ 295.2 $ 118.3